GET DAILY SIGNALSChemomab Therapeutics (CMMB): What to Expect From the Q3 2026 Earnings Report
Key Takeaways
- Chemomab Therapeutics is expected to report third quarter 2026 financial results before the market opens on November 6, 2026.
- As a clinical-stage biotechnology company, Chemomab generates no product revenue, so investors will focus on spending, cash runway, and pipeline milestones rather than top-line sales.
- Wall Street consensus models a net loss of roughly $0.01 per share, reflecting the company's pre-revenue operating profile.
- Cash, cash equivalents, and short-term bank deposits stood at $6.7 million as of June 30, 2026, with management guiding that existing liquidity funds operations into the first quarter of 2027.
- The proposed merger with precision medicine company Scipher Medicine, announced in July 2026, and the advancement of lead candidate nebokitug remain central themes heading into the report.
- For more context on the company, readers can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Investors seeking automated market ideas may also want to explore Trending AI Robots.
Earnings Context and Why It Matters
For Chemomab Therapeutics (CMMB), a clinical-stage biopharmaceutical firm developing treatments for fibro-inflammatory diseases, quarterly earnings are less about revenue and more about financial durability and execution. The company's lead asset, nebokitug, is a monoclonal antibody that targets CCL24, a protein linked to fibrosis and inflammation, with a lead indication in primary sclerosing cholangitis (PSC), a rare liver disease. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial, while a July 2026 merger agreement with Scipher Medicine adds an AI-driven Phase 2 study in rheumatoid arthritis. Against this backdrop, the third quarter report offers a key checkpoint on cash management and R&D progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Chemomab to report a modest net loss, with consensus estimates pointing to a loss of approximately $0.01 per share for the third quarter of 2026. Because the company has no approved product, revenue is not a meaningful metric; instead, investors will scrutinize operating expenses, particularly R&D and G&A spending. In the second quarter of 2026, R&D expenses were $1.1 million and G&A expenses were $1.1 million, yielding a net loss of about $2.2 million. Historical results show consistent quarterly losses, with the most recent quarters improving slightly on a per-share basis as share counts rose. The key figures to watch are the reported net loss, cash balance, and any update to the company's stated cash runway through the first quarter of 2027.
Market Reaction and Investor Sentiment
Sentiment heading into the third quarter report is shaped less by earnings-per-share figures than by strategic developments. Shares of this small-cap biotech have been volatile, reflecting both the binary nature of clinical-stage investing and the company's thin cash position. The announced merger with Scipher Medicine and plans for a Phase 3 nebokitug trial in PSC have provided forward-looking catalysts, but investors remain attentive to financing risk. A narrowing loss or confirmation of the cash runway through early 2027 would likely be viewed favorably, while any indication of accelerated spending or a shortened runway could weigh on the stock. Trading volume is relatively light, which can amplify price moves around earnings. From what I see, this is important because clinical-stage names often move on narrative updates rather than the numbers themselves.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should monitor several items closely. First, any update on the cash runway is critical. With $6.7 million in cash as of June 30, 2026, the company has guided that it can fund operations into the first quarter of 2027, but a clinical-stage firm preparing a Phase 3 trial will likely need additional capital.
Second, the progress of the Scipher Medicine merger is a central storyline. Successful integration and the initiation of an AI-powered Phase 2 study of nebokitug in rheumatoid arthritis could expand the pipeline and potentially strengthen the company's position ahead of the planned Phase 3 PSC trial.
Third, watch for any updates on the Phase 3 PSC trial design and regulatory interactions. Nebokitug already holds Orphan Drug designations from the FDA and EMA as well as FDA Fast Track status for PSC, which may streamline development. Finally, monitor expense trends, as disciplined spending will help extend the runway while the company advances its clinical programs. As always, clinical-stage investing carries meaningful risk, and outcomes will depend heavily on trial results and financing execution. I’m watching this closely as the merger and trial updates unfold.
Exploring Biotech Ideas With AI Tools
In my own research process, I often turn to Tickeron’s AI-powered tools to scan the biotechnology sector and compare names like CMMB against peers on fundamentals and technical signals. The AI Screener lets me apply customizable filters quickly, which helps surface relevant ideas without manual effort. It has become a practical part of how I review small-cap clinical names ahead of events like earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CMMB turns positive, indicating new upward trend
CMMB saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 65 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CMMB's RSI Oscillator exited the oversold zone, 31 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 70 cases where CMMB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on October 27, 2026. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in 195 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day moving average for CMMB crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CMMB entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.055) is normal, around the industry mean (2.904). P/E Ratio (-1.302) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement